Oral semaglutide for weight loss: what the pill can and can't do

What did @realdrbae actually say?

The creator argued that oral semaglutide versions are "not as effective as the injection" because they get "destroyed in the stomach acid." They said even sublingual versions don't reach high enough concentrations to match injectable semaglutide. Their conclusion: oral versions are basically a maintenance tool once you've already lost weight with injections, and you shouldn't expect the same 15% body weight loss. They also noted these are daily, not weekly.

To their credit, they did acknowledge oral semaglutide contains the same active ingredient as injectable versions and isn't an outright scam. That's a meaningful distinction in a space flooded with fake GLP-1 products.

Does the science back this up?

Mostly, yes. The bioavailability argument is the strongest part of this video, and the data supports it. Oral semaglutide (Rybelsus, the FDA-approved version at 14mg daily) produces meaningful but more modest weight loss than injectable Wegovy (2.4mg weekly).

The PIONEER clinical program showed oral semaglutide 14mg reduced body weight by roughly 4-5% over 26 weeks in patients with type 2 diabetes (Aroda et al., 2019, Diabetes Care). The STEP 1 trial for injectable semaglutide showed approximately 14.9% weight reduction over 68 weeks (Wilding et al., 2021, New England Journal of Medicine). Those are not comparable outcomes. The creator's "15%" figure is a reasonable approximation of what the injectable trials showed.

The bioavailability problem is real. Oral semaglutide requires an absorption enhancer (SNAC) to survive gastric acid, and even then, absorption is highly variable and food-dependent. That's not a flaw of one brand. It's a peptide chemistry problem.

What did they get wrong (or right)?

They got the core pharmacology right, but the framing around oral semaglutide as a "maintenance" tool is an oversimplification that isn't well-supported by clinical evidence. There are no robust long-term trials specifically testing oral semaglutide as a weight maintenance strategy after injectable-induced weight loss. That claim is speculative, not established science.

The sublingual claim deserves scrutiny too. The creator says sublingual versions "aren't in high enough concentrations." For compounded sublingual semaglutide specifically, there is very limited peer-reviewed data on absorption, pharmacokinetics, or efficacy. The FDA has not approved any sublingual semaglutide formulation. Presenting this as a known, measured limitation implies more data exists than actually does.

One more thing: referring to the drug repeatedly as "semaglutitis" is a transcript artifact, but the creator's overall framing is clear enough that it doesn't change the substance of the claims.

What should you actually know?

If you're considering oral semaglutide, the only FDA-approved oral version is Rybelsus (14mg), and it was approved for type 2 diabetes management, not specifically for weight loss. It does cause weight reduction, but the evidence for it as a standalone obesity treatment is thinner than for injectable semaglutide.

Compounded oral or sublingual semaglutide products occupy a different regulatory category. Compounded drugs are not FDA-approved, and equivalency to brand-name products cannot be assumed. Doses, absorption rates, and inactive ingredients vary. That doesn't make them automatically unsafe, but anyone using them should understand what the evidence actually shows, which is limited.

• The 14mg oral dose approved by the FDA is the highest studied dose for that formulation.
• Injectable semaglutide reaches peak plasma concentration more predictably than oral versions.
• No published trial has specifically tested oral semaglutide as a post-injection weight maintenance protocol.

The creator's bottom line, that oral semaglutide is less effective than injectable, is accurate. The specific mechanisms they cite are also correct. Where they overreach is in prescribing a clinical use case (maintenance) that the evidence hasn't caught up to yet.